The Asia Pacific Adenosine Triphosphate (ATP) swab test market is expected to reach US$ 81.12 million by 2027 from US$ 41.47 million in 2019. The market is estimated to grow at a CAGR of 8.8% from 2020 to 2027. The growth of the market is attributed to the key driving factors such as rising prevalence of healthcare associated infections (HAI) and increasing emphasis on food safety. However, the limitations of ATP swab tests hinder the market growth.
The ATP Swab test is a fast calculation by identification of adenosine triphosphate or ATP of aggressively developing microorganisms. ATP is a molecule in and near living cells that explicitly tests the organisms’ biological production and well-being. HAIs may cause while receiving treatments or therapies in healthcare facilities. These infections are related to surgical procedures and medical instruments used during operations. The rising prevalence of HAIs is one of the prominent factors driving the demand for ATP swab tests. For instance, according to a study published by the Centers for Disease Control and Prevention (CDC) in 2019, an estimated 1 in 31 hospital patients has some healthcare-associated infection across the globe. Such a substantial prevalence of healthcare-associated disorders propels the adoption of the ATP swab test. Also, the utilization of adenosine triphosphate is a major indicator of cleanliness and sterilization in food & beverages. Hence, the rising incidence of foodborne diseases and food contamination is prominently expected to drive the growth of the Asia Pacific Adenosine Triphosphate (ATP) swab test market during the forecast period.
The COVID-19 outbreak pandemic is adversely affecting countries in Asia Pacific. In Japan, all sanitization processes at hospitals, medical establishments, and high touch point surfaces in public places utilize Adenosine Triphosphate (ATP) Swab Test to confirm the surface is free from microorganisms, which boosts the growth of the Asia Pacific Adenosine Triphosphate (ATP) swab test market. However, the growing number of COVID-19 confirmed cases has resulted in disruption in the supply chain due to a long period of lockdown, which hampers the market growth.
The Asia Pacific Adenosine Triphosphate (ATP) Swab Test market, based on type, is segmented into free ATP test and microbial ATP test. In 2019, the microbial ATP test segment held a larger market share, and the market for the same segment is expected to grow at a faster rate during the coming years.
The Asia Pacific Adenosine Triphosphate (ATP) Swab Test market, based on the application, is segmented into pharmaceutical & biotechnology company, food & beverage, hospitals & diagnostics laboratories, and academic & research institutions. In 2019, the pharmaceutical & biotechnology company segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest rate during the coming years.
A few of the primary and secondary sources referred to while preparing the report on the Asia Pacific Adenosine Triphosphate (ATP) swab test market are the International Trade Administration (ITA), National Health Service (NHS), and World Health Organization (WHO).